Brinley F. Furey

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Ursula A. Germann, Brinley F. Furey, William Markland et al. · Molecular Cancer Therapeutics · 2017 · 234 citations

Medicine, Oncology, Pharmacology +16

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

Amy B. Hall, Dave Newsome, Yuxin Wang et al. · Oncotarget · 2014 · 195 citations · Full text

Medicine, Oncology, Pharmacology +16

Neonatal sex hormones have `organizational' effects on the hypothalamic-pituitary-adrenal axis of male rats

Cheryl M. McCormick, Brinley F. Furey, Meredith Child et al. · Developmental Brain Research · 1998 · 150 citations

Medicine, Endocrinology, Neuroscience +16

Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma

Floris Foijer, Lee A. Albacker, Björn Bakker et al. · eLife · 2017 · 65 citations · Full text

Life Sciences, Genetics, Oncology +17

Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine

Raymond J. Winquist, Diane M. Boucher, Mark Wood et al. · Biochemical Pharmacology · 2009 · 45 citations

Medicine, Cancer Biology, Oncology +16